<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35772216</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3964</ISSN><JournalIssue CitedMedium="Internet"><Volume>81</Volume><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>EBioMedicine</Title><ISOAbbreviation>EBioMedicine</ISOAbbreviation></Journal><ArticleTitle>Evidence of previous SARS-CoV-2 infection in seronegative patients with long COVID.</ArticleTitle><Pagination><StartPage>104129</StartPage><MedlinePgn>104129</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">104129</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2022.104129</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2352-3964(22)00310-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is currently no consensus on the diagnosis, definition, symptoms, or duration of COVID-19 illness. The diagnostic complexity of Long COVID is compounded in many patients who were or might have been infected with SARS-CoV-2 but not tested during the acute illness and/or are SARS-CoV-2 antibody negative.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Given the diagnostic conundrum of Long COVID, we set out to investigate SARS-CoV-2-specific T cell responses in patients with confirmed SARS-CoV-2 infection and/or Long COVID from a cohort of mostly non-hospitalised patients.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">We discovered that IL-2 release (but not IFN-&#x3b3; release) from T cells in response to SARS-CoV-2 peptides is both sensitive (75% +/-13%) and specific (88%+/-7%) for previous SARS-CoV-2 infection &gt;6 months after a positive PCR test. We identified that 42-53% of patients with Long COVID, but without detectable SARS-CoV-2 antibodies, nonetheless have detectable SARS-CoV-2 specific T cell responses.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Our study reveals evidence (detectable T cell mediated IL-2 release) of previous SARS-CoV-2 infection in seronegative patients with Long COVID.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">This work was funded by the Addenbrooke's Charitable Trust (900276 to NS), NIHR award (G112259 to NS) and supported by the NIHR Cambridge Biomedical Research Centre. NJM is supported by the MRC (TSF MR/T032413/1) and NHSBT (WPA15-02). PJL is supported by the Wellcome Trust (PRF 210688/Z/18/Z, 084957/Z/08/Z), a Medical Research Council research grant MR/V011561/1 and the United Kingdom Research and a Innovation COVID Immunology Consortium grant (MR/V028448/1).</AbstractText><CopyrightInformation>Crown Copyright &#xa9; 2022. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krishna</LastName><ForeName>Benjamin A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology &amp; Infectious Disease (CITIID), Cambridge CB2 0AW, UK; Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Eleanor Y</ForeName><Initials>EY</Initials><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology &amp; Infectious Disease (CITIID), Cambridge CB2 0AW, UK; Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK; Department of Infectious Diseases, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mactavous</LastName><ForeName>Lenette</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>NIHR BioResource Team</CollectiveName></Author><Author ValidYN="Y"><LastName>Lyons</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology &amp; Infectious Disease (CITIID), Cambridge CB2 0AW, UK; Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doffinger</LastName><ForeName>Rainer</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Clinical Biochemistry and Immunology, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradley</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK; National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre, Cambridge CB2 0QQ, UK; Cambridge NIHR BioResource Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK; Department of Renal Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Kenneth G C</ForeName><Initials>KGC</Initials><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology &amp; Infectious Disease (CITIID), Cambridge CB2 0AW, UK; Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinclair</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheson</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology &amp; Infectious Disease (CITIID), Cambridge CB2 0AW, UK; Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK; Department of Infectious Diseases, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK; NHS Blood and Transplant, Cambridge CB2 0PT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehner</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology &amp; Infectious Disease (CITIID), Cambridge CB2 0AW, UK; Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK; Department of Infectious Diseases, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wills</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology &amp; Infectious Disease (CITIID), Cambridge CB2 0AW, UK; Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK. Electronic address: mrw1004@cam.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sithole</LastName><ForeName>Nyaradzai</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology &amp; Infectious Disease (CITIID), Cambridge CB2 0AW, UK; Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK; Department of Infectious Diseases, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK. Electronic address: ns519@cam.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/V028448/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_20060</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/V011561/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/T032413/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/S00081X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>EBioMedicine</MedlineTA><NlmUniqueID>101647039</NlmUniqueID><ISSNLinking>2352-3964</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Assay</Keyword><Keyword MajorTopicYN="N">Immunity</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">T cell</Keyword></KeywordList><CoiStatement>Declaration of interests The authors declare no competing interests</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>30</Day><Hour>18</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35772216</ArticleId><ArticleId IdType="pmc">PMC9235296</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2022.104129</ArticleId><ArticleId IdType="pii">S2352-3964(22)00310-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Twohig KA, Nyberg T, Zaidi A, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort study. Lancet Infect Dis. 2022;22(1):35&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8397301</ArticleId><ArticleId IdType="pubmed">34461056</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson EJ, Williams DM, Walker AJ, et&#xa0;al. Risk factors for long COVID: analyses of 10 longitudinal studies and electronic health records in the UK. medRxiv10.1101/2021.06.24.21259277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.24.21259277</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue JK, Franko NM, McCulloch DJ, et al. Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open. 2021;4(2):e210830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen MS, Kristiansen MF, Hanusson KD, et al. Long COVID in the Faroe Islands-a longitudinal study among non-hospitalized patients. Clin Infect Dis Off Publ Infect Dis Soc Am. 2020;73(11):e4058&#x2013;e4063. doi: 10.1093/cid/ciaa1792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1792</ArticleId><ArticleId IdType="pmc">PMC7799340</ArticleId><ArticleId IdType="pubmed">33252665</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickie I, Davenport T, Wakefield D, et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ. 2006;333(7568):575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1569956</ArticleId><ArticleId IdType="pubmed">16950834</ArticleId></ArticleIdList></Reference><Reference><Citation>Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC Neurol. 2011;11 37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3071317</ArticleId><ArticleId IdType="pubmed">21435231</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed H, Patel K, Greenwood DC, et al. Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: a systematic review and meta-analysis. J Rehabil Med. 2020;52(5):jrm00063.</Citation><ArticleIdList><ArticleId IdType="pubmed">32449782</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kessel SA, Olde Hartman TC, Lucassen PL, van Jaarsveld CH. Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. Fam Pract. 2022;39(1):159&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8414057</ArticleId><ArticleId IdType="pubmed">34268556</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabavi N. British Medical Journal Publishing Group; 2020. Long Covid: How to Define it and How to Manage it.</Citation><ArticleIdList><ArticleId IdType="pubmed">32895219</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Woloshin S, Patel N, Kesselheim AS. False negative tests for SARS-CoV-2 infection&#x2014;challenges and implications. N Engl J Med. 2020;383(6):e38.</Citation><ArticleIdList><ArticleId IdType="pubmed">32502334</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H, Hong H, Yoon SH. Diagnostic performance of CT and reverse transcriptase polymerase chain reaction for coronavirus disease 2019: a meta-analysis. Radiology. 2020;296(3):E145&#x2013;E155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233409</ArticleId><ArticleId IdType="pubmed">32301646</ArticleId></ArticleIdList></Reference><Reference><Citation>La Marca A, Capuzzo M, Paglia T, Roli L, Trenti T, Nelson SM. Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays. Reprod Biomed Online. 2020;41(3):483&#x2013;499. doi: 10.1016/j.rbmo.2020.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rbmo.2020.06.001</ArticleId><ArticleId IdType="pmc">PMC7293848</ArticleId><ArticleId IdType="pubmed">32651106</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine-Tiefenbrun M, Yelin I, Uriel H, et al. SARS-CoV-2 RT-qPCR test detection rates are associated with patient age, sex, and time since diagnosis. J Mol Diagn. 2022;24(2):112&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8608683</ArticleId><ArticleId IdType="pubmed">34826637</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins TS, Wu AW, Ting JY. SARS-CoV-2 nasopharyngeal swab testing&#x2014;false-negative results from a pervasive anatomical misconception. JAMA Otolaryngol&#x2013;Head Neck Surg. 2020;146(11):993&#x2013;994.</Citation><ArticleIdList><ArticleId IdType="pubmed">32940647</ArticleId></ArticleIdList></Reference><Reference><Citation>Ameratunga R, Woon S-T, Jordan A, et al. Perspective: diagnostic laboratories should urgently develop T cell assays for SARS-CoV-2 infection. Expert Rev Clin Immunol. 2021;17(5):421&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">33745411</ArticleId></ArticleIdList></Reference><Reference><Citation>Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200&#x2013;1204.</Citation><ArticleIdList><ArticleId IdType="pubmed">32555424</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid decay of anti&#x2013;SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med. 2020;383(11):1085&#x2013;1087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7397184</ArticleId><ArticleId IdType="pubmed">32706954</ArticleId></ArticleIdList></Reference><Reference><Citation>Fergie J, Srivastava A. Immunity to SARS-CoV-2: lessons learned. Front Immunol. 2021;12:716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8018176</ArticleId><ArticleId IdType="pubmed">33815415</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacius A, Tischer-Zimmermann S, Dragon AC, et al. COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. Immunity. 2021;54(2):340&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7871825</ArticleId><ArticleId IdType="pubmed">33567252</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox RJ, Brokstad KA. Not just antibodies: B cells and T cells mediate immunity to COVID-19. Nat Rev Immunol. 2020;20(10):581&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7443809</ArticleId><ArticleId IdType="pubmed">32839569</ArticleId></ArticleIdList></Reference><Reference><Citation>Seow J, Graham C, Merrick B, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020;5(12):1598&#x2013;1607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7610833</ArticleId><ArticleId IdType="pubmed">33106674</ArticleId></ArticleIdList></Reference><Reference><Citation>Dispinseri S, Secchi M, Pirillo MF, et al. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Nat Commun. 2021;12(1):2670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8113594</ArticleId><ArticleId IdType="pubmed">33976165</ArticleId></ArticleIdList></Reference><Reference><Citation>Gans JS, Goldfarb A, Agrawal AK, Sennik S, Stein J, Rosella L. False-positive results in rapid antigen tests for SARS-CoV-2. JAMA. 2022;327(5):485&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8742218</ArticleId><ArticleId IdType="pubmed">34994775</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunstein GD, Schwartz L, Hymel P, Fielding J. False positive results with SARS-CoV-2 RT-PCR tests and how to evaluate a RT-PCR-positive test for the possibility of a false positive result. J Occup Environ Med. 2021;63(3):e159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7934325</ArticleId><ArticleId IdType="pubmed">33405498</ArticleId></ArticleIdList></Reference><Reference><Citation>Pai M, Denkinger CM, Kik SV, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev. 2014;27(1):3&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3910908</ArticleId><ArticleId IdType="pubmed">24396134</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020;183(1):158&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7427556</ArticleId><ArticleId IdType="pubmed">32979941</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherina N, Piralla A, Du L, et al. Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection. Med (N Y) 2021;2(3):281&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7874960</ArticleId><ArticleId IdType="pubmed">33589885</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489&#x2013;1501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7237901</ArticleId><ArticleId IdType="pubmed">32473127</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo J, Dowell AC, Pearce H, et al. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat Immunol. 2021;22(5):620&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7610739</ArticleId><ArticleId IdType="pubmed">33674800</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y, Mentzer AJ, Liu G, et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol. 2020;21(11):1336&#x2013;1345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611020</ArticleId><ArticleId IdType="pubmed">32887977</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrone L, Petruccioli E, Vanini V, et al. A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients. Clin Microbiol Infect. 2021;27(2):286.e7&#x2013;286.e13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7547312</ArticleId><ArticleId IdType="pubmed">33045370</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergamaschi L, Mescia F, Turner L, et al. Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. Immunity. 2021;54(6):1257&#x2013;1275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8125900</ArticleId><ArticleId IdType="pubmed">34051148</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong X, Qu K, Ciazynska KA, et al. A thermostable, closed SARS-CoV-2 spike protein trimer. Nat Struct Mol Biol. 2020;27(10):934&#x2013;941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116388</ArticleId><ArticleId IdType="pubmed">32737467</ArticleId></ArticleIdList></Reference><Reference><Citation>Stadlbauer D, Amanat F, Chromikova V, et al. SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup. Curr Protoc Microbiol. 2020;57(1):e100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7235504</ArticleId><ArticleId IdType="pubmed">32302069</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier DA, Ferreira IA, Kotagiri P, et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021;596(7872):417&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8373615</ArticleId><ArticleId IdType="pubmed">34192737</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson JD, Gibson TJ, Higgins DG. Multiple sequence alignment using ClustalW and ClustalX. Curr Protoc Bioinform. 2003;1(2.3):1&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">18792934</ArticleId></ArticleIdList></Reference><Reference><Citation>Okonechnikov K, Golosova O, Fursov M, Team U. Unipro UGENE: a unified bioinformatics toolkit. Bioinformatics. 2012;28(8):1166&#x2013;1167.</Citation><ArticleIdList><ArticleId IdType="pubmed">22368248</ArticleId></ArticleIdList></Reference><Reference><Citation>Siracusano G, Brombin C, Pastori C, et al. Profiling antibody response patterns in COVID-19: spike S1-reactive IgA signature in the evolution of SARS-CoV-2 infection. Front Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8595940</ArticleId><ArticleId IdType="pubmed">34804064</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan W, Lu Y, Zhang J, et&#xa0;al. Viral kinetics and antibody responses in patients with COVID-19. medRxiv 2020.03.24.20042382</Citation></Reference><Reference><Citation>Xia W, Li M, Wang Y, et al. Longitudinal analysis of antibody decay in convalescent COVID-19 patients. Sci Rep. 2021;11(1):16796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8373894</ArticleId><ArticleId IdType="pubmed">34408200</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang F, Quan Y, Xin Z-T, et al. Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study. J Immunol. 2011;186(12):7264&#x2013;7268.</Citation><ArticleIdList><ArticleId IdType="pubmed">21576510</ArticleId></ArticleIdList></Reference><Reference><Citation>Scurr MJ, Zelek WM, Lippiatt G, et al. Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid-organ cancers. Immunology. 2022;165(2):250&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8653009</ArticleId><ArticleId IdType="pubmed">34775604</ArticleId></ArticleIdList></Reference><Reference><Citation>Thieme CJ, Anft M, Paniskaki K, et al. Robust T cell response toward spike, membrane, and nucleocapsid SARS-CoV-2 proteins is not associated with recovery in critical COVID-19 patients. Cell Rep Med. 2020;1(6)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7456276</ArticleId><ArticleId IdType="pubmed">32904468</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu WJ, Zhao M, Liu K, et al. T-cell immunity of SARS-CoV: implications for vaccine development against MERS-CoV. Antivir Res. 2017;137:82&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7113894</ArticleId><ArticleId IdType="pubmed">27840203</ArticleId></ArticleIdList></Reference><Reference><Citation>Li CK-f, Wu H, Yan H, et al. T cell responses to whole SARS coronavirus in humans. J Immunol. 2008;181(8):5490&#x2013;5500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683413</ArticleId><ArticleId IdType="pubmed">18832706</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh H-LJ, Chia A, Chang CXL, et al. Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope. J Virol. 2011;85(20):10464&#x2013;10471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3187484</ArticleId><ArticleId IdType="pubmed">21813600</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Guan W, Mok CKP, Chen ZL, et al. Characteristics of traveller with Middle East respiratory syndrome, China, 2015. Emerg Infect Dis. 2015;21(12):2278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4672405</ArticleId><ArticleId IdType="pubmed">26583433</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng O-W, Chia A, Tan AT, et al. Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine. 2016;34(17):2008&#x2013;2014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7115611</ArticleId><ArticleId IdType="pubmed">26954467</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherlinger M, Felten R, Gallais F, et al. Refining &#x201c;Long-COVID&#x201d; by a prospective multimodal evaluation of patients with long-term symptoms attributed to SARS-CoV-2 infection. Infect Dis Therapy. 2021;10(3):1747&#x2013;1763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8270770</ArticleId><ArticleId IdType="pubmed">34245450</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacher P, Rosati E, Esser D, et al. Low-avidity CD4+ T cell responses to SARS-CoV-2 in unexposed individuals and humans with severe COVID-19. Immunity. 2020;53(6):1258&#x2013;1271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7689350</ArticleId><ArticleId IdType="pubmed">33296686</ArticleId></ArticleIdList></Reference><Reference><Citation>Doshi P. Covid-19: do many people have pre-existing immunity? BMJ. 2020;370</Citation><ArticleIdList><ArticleId IdType="pubmed">32943427</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner S, Sotzny F, Bauer S, et al. HCoV-and SARS-CoV-2 cross-reactive T cells in CVID patients. Front Immunol. 2020;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7785785</ArticleId><ArticleId IdType="pubmed">33424856</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateus J, Grifoni A, Tarke A, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science. 2020;370(6512):89&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7574914</ArticleId><ArticleId IdType="pubmed">32753554</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M, Grad YH, Sette A, Crotty S. Cross-reactive memory T cells and herd immunity to SARS-CoV-2. Nat Rev Immunol. 2020;20(11):709&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537578</ArticleId><ArticleId IdType="pubmed">33024281</ArticleId></ArticleIdList></Reference><Reference><Citation>Groves HE, Pich&#xe9;-Renaud P-P, Peci A, et al. The impact of the COVID-19 pandemic on influenza, respiratory syncytial virus, and other seasonal respiratory virus circulation in Canada: A population-based study. Lancet Reg Health-Am. 2021;1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8285668</ArticleId><ArticleId IdType="pubmed">34386788</ArticleId></ArticleIdList></Reference><Reference><Citation>Kared H, Redd AD, Bloch EM, et al. SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 individuals. J Clin Investig. 2021;131(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7919723</ArticleId><ArticleId IdType="pubmed">33427749</ArticleId></ArticleIdList></Reference><Reference><Citation>Takagi A, Matsui M. Identification of HLA-A*02:01-restricted candidate epitopes derived from the non-structural polyprotein 1a of SARS-CoV-2 that may be natural targets of CD8(+) T cell recognition in vivo. J Virol. 2020;95(5):e01820&#x2013;e01837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8092843</ArticleId><ArticleId IdType="pubmed">33268522</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>